FIH
Showing 1 - 25 of 510
Multi Vessel Coronary Artery Disease Trial in Leuven, Vilnius (CABG)
Enrolling by invitation
- Multi Vessel Coronary Artery Disease
- CABG
-
Leuven, Belgium
- +1 more
Jan 24, 2023
Peripheral Arterial Disease Trial (Kaitoh Atherectomy System)
Not yet recruiting
- Peripheral Arterial Disease
- Kaitoh Atherectomy System
- (no location specified)
May 23, 2023
STEMI - ST Elevation Myocardial Infarction Trial in Tbilisi, Afula (Booster Balloon Catheter)
Recruiting
- STEMI - ST Elevation Myocardial Infarction
- Booster Balloon Catheter
-
Tbilisi, Georgia
- +1 more
Sep 28, 2022
Chronic Rhinosinusitis Trial (Airiver Nasal Drug Coated Balloon (DCB) Catheter.)
Not yet recruiting
- Chronic Rhinosinusitis
- Airiver Nasal Drug Coated Balloon (DCB) Catheter.
- (no location specified)
May 30, 2023
High-Risk Percutaneous Coronary Intervention Trial in Tbilisi (The Elevate™ System)
Active, not recruiting
- High-Risk Percutaneous Coronary Intervention
- The Elevate™ System
-
Tbilisi, GeorgiaIsraeli-Georgian Medical Research Clinic "Helsicore"
Oct 24, 2023
Colorectal Cancer Trial (Administration of CC-3)
Not yet recruiting
- Colorectal Cancer
- Administration of CC-3
- (no location specified)
Aug 11, 2023
Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases Trial in Boston (IDRX-42)
Recruiting
- Gastrointestinal Stromal Tumor (GIST)
- +3 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Aug 16, 2022
Aortic Valve Stenosis Trial in Petah tikva, Tel Aviv (GEMINUS Transcatheter Aortic Valve Implantation system)
Recruiting
- Aortic Valve Stenosis
- GEMINUS Transcatheter Aortic Valve Implantation system
-
Petah tikva, Israel
- +1 more
Jun 8, 2023
Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis Trial in United States (NRTX-1001, Sham Comparator)
Recruiting
- Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis
- NRTX-1001
- Sham Comparator
-
Palo Alto, California
- +8 more
Jan 23, 2023
Symptomatic Aortic Stenosis Trial in Lithuania, Spain (Vienna Aortic Valve SE System)
Recruiting
- Symptomatic Aortic Stenosis
- Vienna Aortic Valve SE System
-
Kaunas, Lithuania
- +10 more
Sep 27, 2022
Neurodegenerative Diseases Trial in Québec (NS101 IV infusion)
Completed
- Neurodegenerative Diseases
- NS101 IV infusion
-
Québec, CanadaSyneos Health
Dec 21, 2022
Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in United States (REGN5459)
Active, not recruiting
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
-
Indianapolis, Indiana
- +6 more
Aug 16, 2022
PTSD, Alzheimer, Brain Diseases Trial in Liège (Fluoroethylnormemantine (FENM))
Not yet recruiting
- PTSD
- +5 more
- Fluoroethylnormemantine (FENM)
-
Liège, BelgiumCHU of Liège - Clinical Pharmacology Unit
Jun 23, 2023
Ischemia-reperfusion Injury, Kidney Transplant; Complications Trial in Malmö (TUM012, Placebo)
Recruiting
- Ischemia-reperfusion Injury
- Kidney Transplant; Complications
- TUM012
- Placebo
-
Malmö, SwedenHelena Pollard
Apr 5, 2022
Tricuspid Regurgitation Trial in Germany, Israel (Trillium™)
Recruiting
- Tricuspid Regurgitation
- Trillium™
-
Bad Oeynhausen, Germany
- +4 more
Jan 12, 2022
End Stage Renal Disease, End Stage Renal Failure on Dialysis Trial in Worldwide (aXess)
Enrolling by invitation
- End Stage Renal Disease
- End Stage Renal Failure on Dialysis
- aXess
-
Brugge, Belgium
- +4 more
Jan 5, 2022
Corneal Disease, Corneal Opacity, Corneal Injuries Trial in Worldwide (CorNeat KPro)
Recruiting
- Corneal Disease
- +2 more
- CorNeat KPro
-
Edgewood, Kentucky
- +7 more
Apr 24, 2022
Mesial Temporal Lobe Epilepsy Trial in Columbus (AAV9-hSyn1-miGRIK2)
Not yet recruiting
- Mesial Temporal Lobe Epilepsy
- AAV9-hSyn1-miGRIK2
-
Columbus, OhioOhio State University
Sep 25, 2023
Hemophilia A, Hemophilia B, Blood Coagulation Disorders Trial in Seoul (TU7710, Normal saline)
Recruiting
- Hemophilia A
- +2 more
- TU7710
- Normal saline
-
Seoul, Korea, Republic ofSeoul National University Hospital
Sep 8, 2023
Glioblastoma Trial in Boston (ITI-1001)
Not yet recruiting
- Glioblastoma
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 13, 2023